Curi RMB Capital LLC Sells 347,136 Shares of Edwards Lifesciences Co. (NYSE:EW)

Curi RMB Capital LLC cut its stake in Edwards Lifesciences Co. (NYSE:EW) by 93.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 23,295 shares of the medical research company’s stock after selling 347,136 shares during the period. Curi RMB Capital LLC’s holdings in Edwards Lifesciences were worth $1,537,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the 1st quarter valued at about $28,000. First Community Trust NA acquired a new position in shares of Edwards Lifesciences in the second quarter valued at approximately $29,000. Webster Bank N. A. bought a new position in shares of Edwards Lifesciences during the second quarter worth approximately $39,000. Peoples Bank KS acquired a new stake in Edwards Lifesciences during the 3rd quarter worth approximately $40,000. Finally, Versant Capital Management Inc boosted its stake in Edwards Lifesciences by 206.3% in the 2nd quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock valued at $45,000 after purchasing an additional 326 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of a number of research reports. TD Cowen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $100.00 to $70.00 in a report on Thursday, July 25th. Oppenheimer reiterated an “outperform” rating and issued a $90.00 price target on shares of Edwards Lifesciences in a research report on Thursday, September 12th. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Daiwa America lowered Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, Wolfe Research upgraded shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Price Performance

EW stock opened at $67.76 on Friday. The stock has a market cap of $39.96 billion, a PE ratio of 9.78, a P/E/G ratio of 3.74 and a beta of 1.12. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a 50-day moving average price of $67.42 and a 200 day moving average price of $76.37. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, October 24th. The medical research company reported $0.67 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same quarter last year, the business posted $0.59 EPS. The firm’s revenue for the quarter was up 8.9% on a year-over-year basis. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,077,593.52. This trade represents a 9.63 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The trade was a 4.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 41,250 shares of company stock worth $2,744,438 over the last 90 days. Company insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.